Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes

Keywords

Physics, Astrophysics, Stars, Photometry (optics), Stellar rotation

References

• Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.William H Hernan, Michael Brändle, Ping Zhang — 2003
• FAST PRO : software for meta-analysis by the confidence profile methodDavid M. Eddy, Victor Hasselblad — 1992
• Cost-effectiveness in health and medicineM. Gold — 2016
• The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.G. Bray, I. W. Culbert, C. Champagne — 2000
• Onset of NIDDM occurs at Least 4–7 yr Before Clinical DiagnosisMaureen I Harris, Ronald Klein, Tim Welborn — 1992
• Archimedes: a trial-validated model of diabetes.David M. Eddy, Leonard Schlessinger — 2003
• Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.Stephen Colagiuri, C A Cull, Rury R. Holman — 2002
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.Hans-Henrik Parving, Hendrik Lehnert, Jens Brøchner‐Mortensen — 2001
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington — 2004
• Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning.James A. Blumenthal, Andrew Sherwood, Elizabeth C. D. Gullette — 2000
• Archimedes: a new model for simulating health care systems--the mathematical formulationLeonard Schlessinger, David M. Eddy — 2002
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke — 2001
• Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention.Stephanie M. Benjamin, Rodolfo Valdéz, Linda S. Geiss — 2003
• Managing people at high risk for diabetes.William H. Herman, Thomas J. Hoerger, Katherine A. Hicks — 2006
• Validation of the archimedes diabetes model.David M. Eddy, Leonard Schlessinger — 2003
• Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetesHelen M. Colhoun, Margaret J. Thomason, Mike Mackness — 2002
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis — 2002
• Diabetes Therapeutics NewsThomas A. Buchanan, Anny H. Xiang, Ruth Peters — 2002
• Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) TrialSandra J. Lewis, Lemuel A. Moye, Frank M. Sacks — 1998
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.Diabetes Prevention Program Research Group — 2002

Cited by

• Improving the efficiency of lifestyle change interventions for the prevention of cardiometabolic diseaseLutz Kraushaar — 2010
• Infusion of statistical science in comparative effectiveness researchJulio Bernués Pardo, María López-Valdés — 2012
• Efficacy of the Type 2 Diabetes Prevention Using LifeStyle Education Program RCT.護 布川 — 2016
• Lifestyle interventions for diabetes mellitus type 2 prevention.Ramón Sagarra, B Costa, J.J. Cabré — 2014
• Cost-Effectiveness Analysis of Efforts to Reduce Risk of Type 2 Diabetes and Cardiovascular Disease in Southwestern Pennsylvania, 2005-2007Kenneth J. Smith, Heather Hsu, Mark S. Roberts — 2010
• Challenges in prevention and management of diabetes mellitus and metabolic syndrome in IndiaAnkush Desai, Nikhil Tandon — 2009
• DIABETES PREVENTION AND CARDIOVASCULAR RISK REDUCTION IN PRIMARY CARE PRACTICEIN PRIMARY CARE PRACTICEM. Kramer — 2008
• A National Model for Diabetes Prevention and Treatment Program in Civilian and Military Healthcare Beneficiary PopulationsBarbara Barnes, Linda M. Siminerio, Jodi Krall — 2010
• Therapeutic Use of Metformin in Prediabetes and Diabetes PreventionUlrike Gottwald‐Hostalek, Mike Gwilt, Steven Hildemann — 2015
• The Impact of Childhood Measures of Glycemia and Insulin Resistance Factors on Follow-Up Glycemic MeasuresCarol Disbrow Moffett — 2007
• Global views on potential of mobile health solutions to address chronic disease challengesGsma — 2013
• National Strategies to Decrease the Burden of Diabetes and Its ComplicationsJ. Sonya Haw, Shyamanand Tantry, Priyathama Vellanki — 2015
• Epidemiological modelling of type 2 diabetes in Saudi Arabia :predicted trends and public health implicationsAl Quwaidhi, A Abdulkareem Jassem — 2013
• Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomesJulia Dziuba, Peter Alperin, J. Racketa — 2014
• Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysisJulia A. Gaebler, Blickensderfer, Hoogwerf — 2012
• Prevention of type 2 diabetesWilliam C. Knowler — 2015
• 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyDiabetes Prevention Program Research Group — 2009
• Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling studyParinya Chamnan, Rebecca K. Simmons, Kay‐Tee Khaw — 2012
• A Comprehensive Review of Drug–Drug Interactions with MetforminTore Bjerregaard Stage, Kim Brøsen, Mette Marie Hougaard Christensen — 2015
• Optimal diet for glycemia and lipids.William C. Knowler — 2006

Related papers

• High time resolution spectroscopy and magnetic variability of the cool Ap star HD 965V. G. Elkin, D. W. Kurtz, G. Mathys — 2005
• A SEARCH FOR RAPIDLY OSCILLATING AP STARS: I. THE AP-RICH OPEN CLUSTER NGC 2516. II. EVIDENCE FOR OSCILLATIONS IN THE FIELD STAR HD 116763J. M. Matthews, W. H. Wehlau, Tobias J. Kreidl — 1988
• A rival for Babcock's star: the extreme 30-kG variable magnetic field in the Ap star HD 75049V. G. Elkin, G. Mathys, D. W. Kurtz — 2009
• Long-term multicolour photometry and high-resolution spectroscopy of the two gamma Doradus stars HD 12901 and HD 48501C. Aerts, J. Cuypers, P. De Cat — 2004
• Chromospherically Active Stars. XXIV. The Giant, Single-lined Binaries HD 37824, HD 181809, and HD 217188Francis C. Fekel, Gregory W. Henry — 2005
• Binary-induced magnetic activity? - Time-series echelle spectroscopy and photometry of HD 123351 = CZ CVnK. G. Strassmeier, T. A. Carroll, M. Weber — 2011
• Starspots on the fastest rotators in the β Pictoris moving groupD. García-Álvarez, A. F. Lanza, S. Messina — 2011
• The oblique dipole pulsation mode of the rapidly oscillating Ap star HD 80316D. W. Kurtz, Peter Martinez, P. Tripe — 1997
• THE VARIABLE WC 9 STAR HD 164270 REVISITED : A CLOSE BINARY WITH A PRECESSING DISK ?A. F. J. Moffat, R. Lamontagne, Miguela Cerruti — 1986
• Defining the instability strip of pulsating post-AGB binary stars from ASAS and NSVS photometryL. L. Kiss, A. Derekas, Gy. M. Szabó — 2006